Salinomycin, an ionophore antibiotic, has also shown promise, as it downregulated vimentin, upregulated E‐cadherin in colorectal cancer cells, reversed doxorubicin‐induced EMT, and restored chemosensitivity in vitro and in vivo [48]. This evidence concerns the gene CDH1 and colorectal cancer.